Business Context and Reporting Period
Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended September 30, 2002
Business Overview: The Company manufactures and distributes health and wellness products through a direct sales network of independent Distributors and Managers. Operations are segmented geographically into the United States and International regions (Latin America, Asia Pacific, and Other).
Key Financial Metrics
Amounts in thousands, except per share data.
| Metric | 3 Months Ended Sep 30, 2002 | 9 Months Ended Sep 30, 2002 |
|---|---|---|
| Sales Revenue | $73,761 | $227,541 |
| Net Income | $3,478 | $5,609 |
| Diluted EPS | $0.21 | $0.34 |
| Operating Cash Flow | N/A | $9,294 |
| Cash and Equivalents (End of Period) | $24,718 | $24,718 |
| Total Debt | $0 | $0 |
| Working Capital | $35,422 | $35,422 |
Margins (9 Months 2002):
- Gross Margin (Sales less COGS): 82.0%
- Operating Margin: 4.2%
- Net Profit Margin: 2.5%
Material Changes vs. Prior Period
- Revenue Decline: Sales revenue decreased 5.4% in the third quarter and 5.7% for the nine-month period compared to 2001. The decline was driven primarily by international operations, while U.S. sales increased 4.4% in the quarter.
- Profitability Compression: Net income fell 17.6% in the quarter and 56.6% for the nine-month period. Operating income dropped 40.1% (quarter) and 51.4% (nine months).
- Expense Increases: Selling, General, and Administrative (SG&A) expenses increased as a percentage of sales (from 29.8% to 33.7% for the nine months) due to lower sales volume and increased spending on sales conventions and travel.
- Unusual Items: The nine-month period included a $3.0 million impairment charge related to an investment in Cetalon Corporation.
- Segment Performance:
- Latin America: Sales down 13.1% (quarter) due to economic instability in Venezuela and import restrictions in Brazil.
- Asia Pacific: Sales down 36.8% (quarter) primarily due to increased competition in South Korea.
- Other: Sales up 10.6% (quarter), driven by growth in the Russian Federation.
Guidance, Outlook, and Risks
- Outlook: Management expects benefits from new U.S. marketing programs to continue into the fourth quarter. SG&A expenses as a percent of sales are expected to decrease slightly for the remainder of 2002 due to cost controls. The effective tax rate is expected to remain relatively constant.
- Liquidity: Cash decreased by $5.1 million year-to-date, primarily due to $12.2 million in stock repurchases and $3.3 million in capital expenditures. The Company entered a $15.0 million line of credit in Q3; as of November 8, 2002, $5.5 million was utilized for share buybacks.
- Product Liability Risk: The Company faces increased regulatory scrutiny regarding products containing ephedrine alkaloids and kava. Insurance premiums increased 35% with reduced coverage. There is no assurance that adequate insurance will remain available at reasonable costs.
- Foreign Currency Risk: Approximately 41% of revenue is realized outside the U.S. A strengthening U.S. dollar negatively impacts reported sales and expenses. The Company does not use derivative instruments for hedging.
Investor Verification Checklist
- International Exposure: Verify the extent of ongoing economic impacts in Venezuela and Brazil, and competitive pressures in South Korea, as these drove the majority of the revenue decline.
- Insurance Coverage: Confirm the status of product liability insurance for ephedrine and kava-containing products and the potential financial impact of uncovered claims.
- Share Repurchase Program: Review the utilization of the new $15.0 million credit line for stock buybacks and its impact on future liquidity.
- Investment Impairment: Assess the remaining value and future prospects of the Cetalon Corporation investment following the $3.0 million write-down.
- SG&A Efficiency: Monitor whether management's cost control measures successfully reduce SG&A as a percentage of sales in the fourth quarter.